Revolutionizing Cash-Pay Clinic Prescriptions: VITL Secures $7.5M to Enhance E-Prescribing
In recent years, the healthcare landscape has witnessed a significant rise in cash-pay medical establishments, including med-spas, weight-loss clinics, and concierge practices. These facilities offer patients direct access to medical services without the involvement of insurance companies. However, many of these providers still rely on traditional software systems designed for insurance-based care, leading to inefficiencies in managing prescriptions.
Addressing this challenge, VITL, an 18-month-old startup based in Nashville, has developed an e-prescribing platform tailored specifically for cash-pay medical businesses. On March 25, 2026, VITL announced a successful Series A funding round, securing $7.5 million led by venture firm SignalFire.
The Genesis of VITL
Founder and CEO Charlie Jordan established VITL after recognizing the substantial time medical providers spend managing prescriptions for treatments not covered by insurance. Traditionally, providers have relied on faxes or phone calls to send prescriptions to compounding pharmacies—facilities that create custom medications to order. This process often leaves providers and patients uncertain about the final cost and the time required to fill the order.
VITL’s platform addresses these inefficiencies by connecting clinics to a nationwide network of compounding pharmacies. It offers real-time price comparisons and order tracking similar to e-commerce platforms, streamlining the prescription process. We shorten the prescription time from several minutes down to a few seconds, Jordan stated.
Impact and Adoption
The time savings provided by VITL’s platform are significant. For clinics processing numerous orders daily, the reduction in prescription management time accumulates, allowing healthcare providers to focus more on patient care.
Since its launch, VITL has onboarded over 630 clinics and achieved eight figures in annualized recurring revenue (ARR), indicating a revenue of at least $10 million per year. Despite this impressive growth, the company has only tapped into a fraction of the market, which includes tens of thousands of clinics across the United States.
The increasing popularity of GLP-1 drugs—such as Ozempic and Wegovy—peptides, and aesthetic procedures like Botox has contributed to the expansion of cash-pay healthcare businesses. This trend underscores the growing demand for efficient prescription management solutions like those offered by VITL.
Investment and Future Prospects
VITL’s rapid growth attracted the attention of SignalFire, a venture firm known for using data and AI to identify promising companies. Without a formal pitch, SignalFire led the $7.5 million Series A funding round, recognizing the potential of VITL’s innovative approach to e-prescribing.
With this new funding, VITL plans to further enhance its platform, expand its reach to more clinics, and continue addressing the unique needs of cash-pay medical businesses. By streamlining the prescription process, VITL aims to improve operational efficiency for healthcare providers and enhance the overall patient experience.
